The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | Resistance mechanisms in CLL and the importance of genomic re-testing
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses resistance mechanisms in chronic lymphocytic leukemia (CLL), highlighting the importance of genomic testing in this disease. Dr Eichhorst explains that TP53 testing should always be performed at relapse in order to select patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) or to include these patients in clinical trials evaluating CAR-Ts or bispecific antibodies. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
